Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an announcement.
Shanghai Henlius Biotech, Inc. announced that its phase 3 clinical study of HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody injection for treating wet age-related macular degeneration (wAMD), has successfully met its primary endpoint. This development positions the company to potentially enter a market in mainland China where no bevacizumab products have yet been approved for wAMD, indicating a significant opportunity for growth and impact on stakeholders.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of biologic drugs. The company’s primary products include monoclonal antibodies, with a market focus on innovative treatments for various diseases, including ophthalmic conditions.
YTD Price Performance: 51.05%
Average Trading Volume: 1,565,366
Technical Sentiment Signal: Sell
Current Market Cap: HK$18.67B
See more data about 2696 stock on TipRanks’ Stock Analysis page.